Economic Model For Antibiotics Is Broken, AstraZeneca’s Rex Says
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
A better economic model for anti-infective research would include incentives to start antibiotic R&D, AstraZeneca exec John Rex tells ICAAC, and go beyond current initiatives that provide financial relief after a new antibiotic is developed.
You may also be interested in...
FDA Worries About Off-Label Use, Stewardship With Limited-Population Approval Pathway
FDA asks groups how it can help ensure prescribing is limited for products approved under proposed new pathway, but several say, other than labeling, it may be out of the agency’s hands.
With GAIN In Place, Antibiotic Improvements Depend On FDA Implementation
FDA and industry are turning their attention to implementation of the Generating Antibiotic Incentives Now provisions of PDUFA V, which include an additional five years of marketing exclusivity for certain products and new guidance aimed at streamlining the drug development process.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.